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The biomolecule interface is a key element in immunosensor fabrication, which can greatly influence the sensor performance.
This paper explores the effects of surface epitope coverage of small molecule functionalized nanoparticle on the apparent affinity
(avidity) of antibody in a competitive inhibition assay using bisphenol-A (BPA) as amodel target. An unconventional two-antibody
competitive inhibition ELISA (ci-ELISA) using thiolated BPAmodified gold nanoparticles (cysBPAv-AuNP) as a competing reagent
was devised for this study. It was shown that the antibody complexation with cysBPAv-AuNPs required a minimum number of
surface epitopes on the nanoparticle to form a sufficiently strong interaction and reliable detection.The binding of cysBPAv-AuNP
to anti-BPA antibodies, for limited antibody binding sites, was enhanced by a greater number of epitope-modified nanoparticles
(cysBPAv-AuNP) as well as with higher epitope coverage. Increasing the molar concentration of epitope present in an assay
enhanced the binding between anti-BPA antibodies and cysBPAv-AuNP. This implies that, to increase the limit of detection of a
competitive inhibition assay, a reducedmolar concentration of epitope should be applied.This could be achieved by either lowering
the epitope coverage on each cysBPAv-AuNP or the assay molar concentration of cysBPAv-AuNP or both of these factors.
1. Introduction
Due to the size-dependent optical and electronic properties
of gold nanoparticles (AuNPs), the volume of literature on
their application in sensing is immense [1–3]. In electrochem-
ical sensors, AuNPs have been used to enhance refractive
index changes [4, 5], increase the surface-volume ratio,
provide high conductivity, and accelerate electron transfer
to a redox active species [6–8]. To fabricate AuNPs-based
biosensors, AuNPs have been modified with short peptides
or organic molecules [8, 9]. The organic molecules could
be a ligand or an epitope to which an antibody could
specifically bind. The modification of AuNPs with small
organic molecules is a construct with considerable potential,
particularly in immunosensing. Amplification of analytical
signals that are made possible by gold nanoparticles is
even more important for small molecule detection than
macromolecule detection. The antibody binding of small
molecules to a biosensing interface is notoriously hard to
detect otherwise. To date, however, the vast majority of
studies employing organic molecule functionalized AuNPs
are motivated towards detecting protein [3, 8, 10] rather than
small molecules such as pesticides, endocrine disruptors, and
pharmaceutical or veterinary drugs.
The most relevant study where gold nanoparticles are
used in immunosensing for detecting small molecules is
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by Taguchi et al. [11]. In that study, an analogue of the
endocrine disruptor, bisphenol-A (BPA), was used to modify
AuNPs for the fabrication of a competitive surface plasmon
resonance (SPR) based sensor. This competitive assay for
smallmolecules had a limit of detection of 0.1mM(equivalent
to 22.8mg L−1). The relevance of the Taguchi study for the
present work is that AuNPs modified with small organic
molecules are a central component in an immunoassay.
We are interested in using organic modified nanoparticles
in ELISA and as analogues of hapten-protein conjugates
for the generation of antibodies. There have not been any
studies in which gold nanoparticles modified with a small
organic molecule epitope have been characterized using
the standard tool of immunochemistry. The combination
of ELISA and nanoparticles is potentially useful, not only
as a rapid approach to characterizing the functionality of a
nanoparticle as a sensing element [6, 10], but also as an assay
reagent.
Small molecule analytes are typically quantified by a
competitive inhibition format in an immunoassay [12]. Based
on the law of mass action, assay sensitivity is proportional
to the value of equilibrium constant (i.e., the amount of the
antigen-antibody complex). In a competitive inhibition assay,
there are two equilibrium constants to be considered; the
equilibrium constant involving the antigen itself is denoted
by𝐾
𝑎
and the other involving the labelled competing antigen
(often referred to as hapten) is denoted by 𝐾
𝑎
∗ , as illustrated





































Assay sensitivity is predominantly influenced by two factors:
(1) the relative affinity of an antibody between the target
molecule ([Ag]) and the competing hapten ([Ag∗]) which
is labelled with an enzyme for measurement and (2) the
epitope density of the competing hapten coupled to an




∗). For the first factor,
selection of an appropriate hapten structure with a right
linker for the enzyme conjugation is critical in achieving
the greatest possible sensitivity by controlling the relative
affinity of the antibody between the target molecule and




∗). For the second
factor, the epitope density of the hapten-enzyme conjugate
provides multivalence in order to enhance the binding
affinity, particularly useful for the weak binding antibodies
in a polyclonal population. This phenomenon has been well
demonstrated in many immunoassays developed for small
molecules such as endocrine disrupting chemicals, pesticides,
and mycotoxins [13, 14]. The concentration of the competing
hapten in an assay influences the assay affinity (i.e., avidity)
in a competitive immunoassay. The concentration of the
competing hapten in an assay is generally determined as the
concentration of the conjugate concentration rather than the
concentration of hapten.This is because the epitope density of
the hapten-enzyme conjugate is heterogeneous and could not
be readily determined. Therefore, batch-to-batch variation
is typical, making quality control of assay reagents such as
hapten-enzyme conjugate somewhat difficult.
Nanoparticles can serve as a good platform for targeted
functionalization with small molecule epitopes. The purpose
of this paper is to demonstrate the application ofAuNPsmod-
ified with small molecule epitopes for binding to antibodies
in a competitive inhibition format. More importantly, the
ability of the AuNPs to support multiple either homologous
or heterologous epitopes means that more than one antibody
can bind to theAuNPs in amanner reminiscent of a sandwich
ELISA although the nature of the ELISA is a competitive
inhibition. Given the inherent complexities of the interaction
of surface epitopes with antibodies, however, which may be
different then the biological conjugate (e.g., protein-hapten
conjugates) in a competitive inhibition event, we sought to
investigate factors that may affect the antibody-surface epi-
tope interaction and the subsequent analytical performance
in a competitive inhibition assay. A better understanding of
quantitative relationship between structure and activity in
terms of avidity relating to multivalent interaction in a com-
petitive inhibitionmannerwill provide information about the
future design of targeted nanoparticles for immunosensing of
small molecule analytes. In this study, the surface bound epi-
tope is a thiolated bisphenol-A derivative and the antibodies
used are anti-BPA antibodies we have described previously
[15].
2. Experimental
2.1. Materials. 4,4-Bis(4-hydroxyphenyl)valeric acid (BPA-
valeric acid), N-hydroxysuccinimide (NHS), N,N󸀠-dicy-
clohexylcarbodiimide (DCC), dimethyl sulfoxide (DMSO),
3,3󸀠,5,5󸀠-tetramethylbenzidine (TMB), Tween-20, and
avidin-horseradish peroxidase (HRP) were purchased from
Sigma-Aldrich (Sydney, Australia). Absolute ethanol (EtOH),
methanol (MeOH), and sulphuric acid were obtained from
Ajax Finechem (Sydney, Australia). Disodium hydrogen
phosphate, monosodium phosphate, and sodium chloride
were sourced BDH Chemicals (Melbourne, Australia).
MaxiSorp polystyrene 96-well plates were obtained from
Nunc (Roskilde, Denmark). Ultrapure water was from
either a Millipore Milli-Q Academic System (18.2MΩ⋅cm)
or a Sartorius arium 61316/611VF (17.6MΩ cm). Skim milk
powder was purchased from a local supermarket (NSW,
Australia). The preparation of the cysteamine-BPA-valerate
ligand (cysBPAv), gold nanoparticles (AuNPs), anti-BPA
antibodies (referred to as Ab∝BPA-V2#4), and BPA-valerate-
BSA and the conjugation of antibodies and biotin (referred to
as Ab∝BPA-V2#4-biotin) were described previously [14, 15].
2.2. Instrumentation. An ELISA plate reader (SpectroMax
M2) was obtained from Molecular Devices (Sunnyvale,
USA). Centrifugation was performed using a Sigma 1-
14 Laboratory Table Top Microcentrifuge (16,163×g for
15min). Nuclear magnetic resonance (NMR) measurements
were performed on a Bruker Avance III 300MHz. UV-Vis
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measurements were performed on a Varian Cary 50 Bio UV-
Visible spectrophotometer.
2.3. Modification of AuNPs. Based on modification of the
AuNPs described previously [16], different volumes (13,
15, 20, 30, and 60 𝜇L) of 1mmol L−1 of BPA modified
compound, cysBPAv, in EtOH were added to 1mL of the
above AuNPs solution, and then the mixture was allowed
to stand at room temperature overnight in the dark to syn-
thesize cysBPAv-AuNP-160, cysBPAv-AuNP-190, cysBPAv-
AuNP-265, cysBPAv-AuNP-396, and cysBPAv-AuNP-801,
respectively. After centrifugation (16,163×g for 15min), the
pellet was resuspended in 100𝜇L EtOH and then diluted with
900𝜇L of Milli-Q water. The number of cysBPAv ligands
conjugated per nanoparticle depicted in parentheses (e.g.,
cysBPAv-AuNP-190 corresponds to particle cysBPAv-AuNP
with 190 conjugated ligands) was calculated based on the
indirect competitive ELISA (i-ELISA) results of the amount
of unconjugated thiolated ligand.
2.4. Preparation of BPA Standard. Standard stock solution
(1 × 106 𝜇g L−1) of BPA was prepared by dissolving an
appropriate amount of BPA in MeOH. Working standard
solutions (0.51–10,000𝜇g L−1) were prepared by diluting the
stock solution in 10% EtOH/phosphate buffered saline (PBS)
just before use.
2.5. i-ELISA. The % conjugation of cysBPAv to AuNP was
determined by measuring the amount of unconjugated cys-
BPAv remaining in the supernatant by i-ELISA. The i-ELISA
was conducted as follows. BPA-valerate-BSA was immobi-
lized onto amicroplate at 10𝜇gmL−1.Themicrowell plate was
washed three times with washing solution (0.05% Tween-20)
and blocked with 3% skimmilk power in PBS (pH 7.4) for 1 h.
After washing the plate as previously described, the cysBPAv
standard solutions andAb∝BPA-V2#4 antiserumwere added
to the respective wells and the mixture was incubated for 1 h.
The plate was washed 4 times with washing solution, and the
anti-rabbit IgG conjugate dissolved in PBS was added to all
the wells and the mixture was incubated for 30min. After
washing the plate five times, substrate solution (TMB) was
added to all the wells to develop the color. The color reaction
was stopped after 20min by adding 50 𝜇L of 1.25mol L−1
sulphuric acid into each well and the absorbance values of
the wells were measured at 450 nm. In this way, the more
unconjugated cysBPAv are in solution, the less Ab∝BPA-
V2#4 binds to the immobilized BPA-valerate-BSA and hence
the lower absorbance after the color reaction is.
2.6. Two-Antibody Competitive Inhibition ELISA (ci-ELISA).
Microwells were immobilized with Ab∝BPA-V2#4 antibody
at 10 𝜇gmL−1. After washing the microwell plate three times
with the washing solution, 1% soybean protein in PBS (SBP-
PBS, pH 7.4) was incubated in the wells for 1 h. The plate
was washed 3 times again. BPA standard solutions in 10%
EtOH/PBS and cysBPAv-AuNPs in 10% EtOH/PBS were
added to the respective wells and the mixture was incubated
for 30min. The plate was washed again, and Ab∝BPA-V2#4-
biotin in 10% EtOH/PBS was added and incubated for 1 h.
After washing the plate, avidin-HRP conjugate in PBS was
added to the wells and incubated for 30min. The plate was
washed 5 times this time to remove any unbound reagents
and nanoparticles; then substrate solution (TMB) was added
to all the wells to develop the color. The absorbance values
weremeasured at 450 nm after the color reactionwas stopped
after 20min by adding 50 𝜇L of 1.25mol L−1 sulphuric acid
(Figure 1).
3. Results and Discussion
3.1. Characterization of Functionalized Gold Nanoparticles
withDifferent Epitope Coverage. Thesynthesis and character-
ization of unmodified AuNP were reported previously [16].
The average size of the unmodified AuNPs was determined
to be 5.3 ± 1.6 nm using the TEM images. The concentration
of AuNPs solution was estimated to be 6.35 × 10−8mol L−1,
which was calculated based on the extinction coefficient of
the AuNPs of 7.20 × 106M−1 cm−1 [16]. The nanoparticles
were modified with thiolated BPA via sulfhydryl exchange
and denoted by cysBPAv-AuNPs. The estimated number of
cysBPAv ligands conjugated per nanoparticle is appended to
the particle name (e.g., cysBPAv-AuNP-190 corresponds to
particle cysBPAv-AuNPwith 190 conjugated ligands) andwas
calculated based on the indirect competitive ELISA (i-ELISA)
results of the amount of unconjugated thiolated ligand as
described in Section 2.5. The modified particles with differ-
ent surface epitope coverage (cysBPAv-AuNP-163, cysBPAv-
AuNP-190, cysBPAv-AuNP-265, cysBPAv-AuNP-396, and
cysBPAv-AuNP-801) were estimated to have the epitope
coverage of 3.0 × 10−10, 3.6 × 10−10, 4.9 × 10−10, 7.4 × 10−10,
and 15.0 × 10−10mol cm−2, respectively, or an average of 163,
190, 265, 396, and 801 epitopes per particle (Table 1).
3.2. Characterization of cysBPAv-AuNPs Using i-ELISA. The
surface epitope coverage affecting the avidity of theAb∝BPA-
V2#4 antibody for the nanoparticles modified with the 5
different epitope coverage was studied using the indirect-
ELISA at the nanoparticle molar concentrations in the range
between 3.7 × 10−10 and 4.7 × 10−13mol L−1. As the Stokes-
Einstein radius of IgG (56 Å) is relative to the average diam-
eter of AuNP (5 nm), we made an assumption that only one
cysBPAv-AuNP will bind to one antibody at each incubation
step largely due to the steric constraints [15, 17]. Upon
binding to the immobilized antibody, the remaining cysBPAv
epitopes on the nanoparticle are potentially free to bind to the
Ab∝BPA-V2#4-biotin conjugate as the detection antibody
much like a sandwich-like configuration. The antibody-
epitope binding was determined using a HRP-streptavidin
conjugate that complexes with the biotinylated detection
antibody.The use of avidin-biotin system in this assay proved
to lower the nonspecific binding as well as allowing for
signal amplification for more reliable measurement (data not
shown).
The surface epitope coverage was estimated to span a
range from 3.0 × 10−10 to 15 × 10−10mol cm−2 (Table 1),
representing an approximately fivefold change in the epi-
tope molar concentrations. As illustrated in Figure 2, the
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Table 1: The epitope coverage and 𝐾
𝑑
of each cysBPAv-AuNP.
CysBPAv-AuNP Epitope coverage (mol cm−2) Surface epitopes per AuNP % Surface coverage 𝐾
𝑑
(×10−8mol L−1)
CysBPAv-AuNP-163 3.0 × 10−10 163 20 —
CysBPAv-AuNP-190 3.6 × 10−10 190 24 6.8 ± 2.9
CysBPAv-AuNP-265 4.9 × 10−10 265 33 2.3 ± 0.9
CysBPAv-AuNP-396 7.4 × 10−10 396 50 1.3 ± 0.4
CysBPAv-AuNP-801 15.0 × 10−10 801 100 0.48 ± 0.06















































Figure 1: The configuration of ci-ELISA.
absorbance increased with increasing epitope coverage on
the nanoparticles. Nanoparticles with lower epitope coverage
required higher molar particle concentrations to reach the
same absorbance value as those with higher epitope coverage
which required lower molar particle concentrations. For
instance, the absorbance generated using 3 × 10−10mol L−1
cysBPAv-AuNP-163 (i.e., particle with lower epitope cov-
erage) was the same as using 8 × 10−11mol L−1 cysBPAv-
AuNP-801 (i.e., particle with higher epitope coverage). This
indicated that the interaction between cysBPAv epitopes and
antibodies particularly with the biotinylated antibody was
facilitated by having multiple epitopes on the nanoparticles,
which enhanced the binding strength (avidity). Based on
the calculated epitope coverage, minimum of approximately
160 epitopes per particle (estimated to be roughly 20%
surface coverage) was needed to generate a detectable and
reproducible signal. Below this number, the antibody binding
showed large deviation in themeasurement (data not shown).
The surface epitope coverage also affected the molar
concentrations of nanoparticles at which the binding event
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Figure 2: The dose-response relationship between molar concen-
trations of surface epitopes on cysBPAv-AuNPs and Ab∝BPA-V2#4
(1 × 104 𝜇g L−1). e = cysBPAv-AuNP-163; △ = cysBPAv-AuNP-190;
× = cysBPAv-AuNP-265; ◻ = cysBPAv-AuNP-396; 󳶃 = cysBPAv-
AuNP-801.
could be detectable, and the range of molar concentra-
tions of nanoparticles showed strong antibody binding. The
equilibrium dissociation constants (𝐾
𝑑
) of cysBPAv-AuNP-
190, cysBPAv-AuNP-265, cysBPAv-AuNP-396, and cysBPAv-
AuNP-801 were 6.8 ± 2.9 × 10−8, 2.3 ± 0.9 × 10−8, 1.3 ± 0.4 ×
10−8, and 0.48 ± 0.06 × 10−8mol L−1 (Table 1). The 𝐾
𝑑
for
cysBPAv-AuNP-163 could not be estimated due to the large
variation in the binding data. The decrease in 𝐾
𝑑
values with
increase in surface epitope coverage clearly demonstrated
that multivalent surface ligand does increase the affinity of
antibody. The minimum molar nanoparticle concentration
of cysBPAv-AuNP-163 showing the antibody binding was
1.0 × 10−10mol L−1. The cysBPAv-AuNP-801 nanoparticles,
which had five times more epitopes than cysBPAv-AuNP-
163, showed the antibody binding at the molar nanopar-
ticle concentration 200 times lower than that of cysBPAv-
AuNP-163. Increasing surface epitope coverage of function-
alized nanoparticles decreased the molar concentration of
nanoparticle required for the antibody binding exponentially
(Figure 2).
In short, these results show the importance of surface
epitope coverage in providing more efficient multivalent
interaction between antibody and surface epitopes in enhanc-
ing the assay avidity. Such findings are also observed in the
previous studies using noncompetitive assays [18–20].
3.3. ci-ELISA under Different Molar Concentrations of
cysBPAv-AuNP-265. In order to study the relationship
between surface epitope coverage (on nanoparticles) and
multivalent interaction with an antibody, a competitive
inhibition enzyme-linked immunosorbent assay (ci-ELISA)
using two BPA-specific antibodies was devised. In this assay,
the free BPA and cysBPAv-AuNP were allowed to compete
with each other to bind to the immobilized antibody. The
signal was generated via the second biotinylated antibody
binding to the bound cysBPAv-AuNP. Avidin-HRP/TMB
substrate system was added to generate the colorimetric
signal. If free BPA was bound to an antibody, then this
binding site was no longer free to bind to the cysBPAv-AuNP
and hence does not generate color. CysBPAv-AuNP, on the
other hand, had multivalent epitopes conjugated to the
particle surface, some of which would still be available to
bind to the biotinylated antibody. Therefore, the ci-ELISA
devised in this manner could be used to quantify free BPA
based on the degree of cysBPAv-AuNP competitively bound
to the immobilized antibody relative to the free BPA. As
for a competitive assay, the color development is inversely
proportional to the concentration of free BPA.
The three factors selected for the study were the surface
epitope coverage, the molar concentration of epitope in an
assay, and the molar concentration of particle (i.e., cysBPAv-
AuNPs). In an ELISA, both the epitope coverage of hapten-
protein conjugates and concentration of epitope in an assay
influence the linear detection range and an IC
50
. Thus, the
epitope coverage of competing hapten-protein conjugate and
its quantity in an assay are typically optimised to yield the
lowest IC
50
. So it was relevant to study these factors with
nanoparticles functionalized with small molecule epitopes.
Nanoparticles serve as carriers of epitopes in this study; how-
ever, their physical structures may interfere with antibody-
antigen interaction. Whether the diffusion of nanoparticle,
which is dependent on their concentrations, influences the
antibody binding to the surface epitope in a competitive assay
has yet to be explored.
In the first experiment, the surface epitope coverage was
fixed by using cysBPAv-AuNP-265 to investigate the effects
of the molar concentration of nanoparticles and the molar
concentration of epitopes in an assay on the competitive bind-
ing. The three molar concentrations of nanoparticles (6.6 ×
10−10mol L−1, 3.3 × 10−10mol L−1, and 1.3 × 10−10mol L−1)
selected were above the minimum particle concentration
required for generating detectable signal in the indirect
ELISA as determined above (1.2 × 10−11mol L−1 of cysBPAv-
AuNP-265).
From the results (Figures 3(a) and 3(b) andTable 2), a typ-
ical sigmoidal curve of the competitive inhibition assay was
observed, showing a decrease in absorbance with an increase
in free BPA concentration. This indicated that the cysBPAv-
AuNP behaved much like a multivalent hapten-protein con-
jugate in an immunoassay. As shown in Figure 3(b) and
Table 2, the IC
50
value decreased eightfold (from 8𝜇mol L−1
to 1.2 𝜇mol L−1 BPA) when the molar concentration of
cysBPAv-AuNPswas reduced roughly 5-fold (from6.6× 10−10
to 1.3 × 10−10mol L−1). When the molar concentration of
cysBPAv-AuNPs decreased from 6.6 × 10−10mol L−1 to 1.3 ×
10−10mol L−1, the affinity constants (𝐾
𝑎
) for the respective
molar concentration of surface epitopes were 0.13 ± 0.02,
0.23 ± 0.03, and 0.62 ± 0.09 L 𝜇mol−1, showing the binding
affinity of antibody for BPA increased with the decrease of
the surface epitopes. This result indicates that the molar
concentration of nanoparticle and the molar concentration
of epitope in an assay had a significant influence on the
linear detection range and limit of detection in a competitive
inhibition assay of this type.The assay sensitivity asmeasured
by the slope of the standard curves was not significantly
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Table 2: Assay parameters and calculated affinity constant derived from Figure 3.
Nanoparticle 265 (e) 265 (◻) 265 (󳵳)
Particle number (mol L−1) 6.6 × 10−10 3.3 × 10−10 1.3 × 10−10
Molar concentration of surface epitope (mol L−1) 1.7 × 10−7 9.0 × 10−8 3.0 × 10−8
Slope from Figure 3(b) 1.1 ± 0.11 0.87 ± 0.07 0.88 ± 0.13
IC
50
(𝜇mol L−1) 8.0 ± 1.5 4.4 ± 1.2 1.2 ± 1.2
Affinity constant (𝐾
𝑎
, 𝜇mol−1) 0.13 ± 0.02 0.23 ± 0.03 0.62 ± 0.09
Linear detection range∗ (𝜇mol L−1) 1.9–30.2 0.9–18.6 0.2–5.6
∗20–80% of the%𝐼 curve.




































Figure 3: Dose-response curves of the ci-ELISA under the same epitope coverage. The absorbance curve (a) and inhibition curve using the
molar concentration of cysBPAv-AuNP in an assay (b). e = 6.6 × 10−10mol L−1 cysBPAv-AuNP-265 (molar concentration of epitope in an
assay: 1.70 × 10−7mol L−1); ◻ = 3.3 × 10−10mol L−1 cysBPAv-AuNP-265 (molar concentration of epitope in an assay: 9.00 × 10−8mol L−1); 󳵳 =
1.3 × 10−10mol cysBPAv-AuNP-265 L−1 (molar concentration of epitope in an assay: 4.00 × 10−8mol L−1).
influenced by the concentration of particles or epitopes. This
is consistent with the assumption that AuNPs serve as a
carrier for epitopes but do not participate in the binding
process themselves.
3.4. ci-ELISA under the Same Molar Concentration of
cysBPAv-AuNP-190, cysBPAv-AuNP-396, and cysBPAv-
AuNP-801. In a second set of experiments, cysBPAv-
AuNP-190, cysBPAv-AuNP-396, and cysBPAv-AuNP-801
were selected to study the effects of surface epitope cover-
age and the molar concentration of epitope in an assay
without changing the amount of particles. The nanoparticle
concentration was fixed at 2.1 × 10−10mol L−1. Consequently,
the molar concentrations of the surface epitope in an assay
changed fourfold (4.0 × 10−8mol L−1 for cysBPAv-AuNP-
190, 8.0 × 10−8mol L−1 for cysBPAv-AuNP-396, and 1.7 ×
10−7mol L−1 for cysBPAv-AuNP-801).
It was noted that, at lower epitope concentration or
lower surface epitope coverage, less free BPA was required
to compete with the nanoparticles for antibody binding
sites (Figure 4 and Table 3). That is, the IC
50
decreased with
a decrease in surface epitope coverage as did the linear
detection range. Naturally, of course, this also means the
molar concentration of the surface epitope also showed dose
dependent effects. However, in contrast to the concentration
of nanoparticles discussed in Section 3.4, the sensitivity was
affected by the surface epitope coverage and reduced at higher
surface epitope coverage as evidenced by the lower slope
of the cysBPAv-AuNP-801 dose-response curve. The affinity
constants of the antibody for cysBPAv-AuNP-190, cysBPAv-
AuNP-396, and cysBPAv-AuNP-801 decreased with increas-
ing surface epitopes (Figure 4 and Table 3). These results
indicated that the binding affinity of antibody to the surface
epitope was likely to be dominated by the concentration
of particles. Both surface epitope coverage and the molar
concentration of epitope in an assay influenced the apparent
sensitivity. It was not possible, however, to distinguish which
of the two factors influenced this parameter more strongly.
3.5. ci-ELISA with the Same Molar Concentration of Epitope
in an Assay of cysBPAv-AuNP-190, cysBPAv-AuNP-396, and
cysBPAv-AuNP-801. Finally, in the third set of experiments,
the molar concentration of epitope in an assay was fixed
at 1.01 × 10−7mol L−1 in order to compare the effects of
the surface epitope coverage and the molar concentration
of particle in assay performance. The selected cysBPAv-
AuNP, therefore, exhibited different particle molar concen-
trations. The cysBPAv-AuNP with the lowest surface epitope
coverage had the highest molar concentration of particle
in an assay: cysBPAv-AuNP-190 at particle concentration
Journal of Nanomaterials 7
Table 3: Assay parameters and calculated affinity constant derived from Figure 4.
Nanoparticle 190 (e) 396 (◻) 801 (󳵳)
Particle number (mol L−1) 2.1 × 10−10 2.1 × 10−10 2.1 × 10−10
Molar concentration of surface epitope (mol L−1) 4.0 × 10−8 8.0 × 10−8 1.7 × 10−7
Slope from Figure 4(b) 0.68 ± 0.08 0.81 ± 0.10 0.36 ± 0.14
IC
50
(𝜇mol L−1) 0.7 ± 1.2 1.8 ± 1.2 20.0 ± 15.4
Affinity constant (𝐾
𝑎
, 𝜇mol−1) 1.1 ± 0.2 0.55 ± 0.08 0.34 ± 0.10
Linear detection range∗ (𝜇mol L−1) 0.09–5.2 0.32–11.8 0.20–44.7
∗20–80% of the%𝐼 curve.


































Figure 4: Dose-response curves of the ci-ELISA under the same molar concentration of particle in an assay. Absorbance curve (a) and
inhibition curve (b) of the c-ELISA conducted using the same molar concentration cysBPAv-AuNP. e = 2.1 × 10−10mol cysBPAv-AuNP-
190 L−1 (the concentration of epitope in an assay: 4.0 × 10−8mol L−1); ◻ = 2.1 × 10−10mol cysBPA-AuNP-396 L−1 (the concentration of epitope
in an assay: 8.0 × 10−8mol L−1); 󳵳 = 2.1 × 10−10mol cysBPA-AuNP-801 L−1 (the concentration of epitope in an assay: 1.7 × 10−7mol L−1).
of 5.3 × 10−10mol L−1, cysBPAv-AuNP-396 at the particle
concentration of 2.6 × 10−10mol L−1, and cysBPAv-AuNP-801
at the particle concentration of 1.3 × 10−10mol L−1.
As shown in Figure 5 and Table 4, the nanoparticles
with different surface epitope coverage, particularly cysBPAv-
AuNP-190 and cysBPAv-AuNP-396, exhibited similar max-
imum absorbance values (i.e., absorbance at saturation),
sensitivities, and IC
50
values. The affinity constants of these
nanoparticles at the same molar surface epitope concen-
tration had no significant difference. The almost overlap-
ping of the dose-response curves suggested that the molar
concentration of nanoparticles probably had little effects on
the competitive inhibition between free BPA and cysBPAv-
AuNP for the antibody binding.This result again supports the
assertion that the AuNPs are simply carriers for the epitopes
and it is the epitope concentration and surface coverage that
are the important variables for the assay sensitivity.
4. Conclusions
Interaction between an antibody and multivalent surface
epitopes is a means to enhance antibody avidity for weak
binding antigens.The effects of multivalent interaction in the
competitive inhibition assay, however, have not previously
been studied. In this study, we explored the interaction
between an antibody and multivalent surface epitopes of a
small molecule in a competitive inhibition assay. The com-
petitive inhibition assay using a 96-microwell platform was
devised using the two-antibody approach with the avidin-
biotin signal enhancement system. Surface epitopes with
varying epitope densities were synthesized by functionalizing
AuNPs with various quantities of cysBPAv to yield surface
coverage between 163 and 801 epitopes per nanoparticle.
The surface epitope coverage influenced the antibody
avidity which was increased with higher surface epitope cov-
erage. There was minimum surface epitope coverage which
was required to give reliable antibody-epitope interaction for
detection, and this value should be determined for each dif-
ferent platform. In this study, the minimum epitope coverage
was estimated to be 163 epitopes per nanoparticle which was
equivalent to 20% coverage.Higher surface epitopes provided
stronger and more consistent interaction between antibody
and surface epitopes.
The three different sets of competitive inhibition exper-
iments conducted suggested that all three studied factors
(i.e., surface epitope coverage, assay molar nanoparticle
concentration, and assay molar concentration of epitope)
affected the assay affinity, but each to different degree, and
these factors were related with one another. The surface
epitope coverage was important in increasing the avidity
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Table 4: Assay parameters and calculated affinity constant derived from Figure 5.
Nanoparticle 190 (e) 396 (◻) 801 (󳵳)
Particle number (mol L−1) 5.3 × 10−10 2.6 × 10−10 1.3 × 10−10
Molar concentration of surface epitope (mol L−1) 1.0 × 10−7 1.0 × 10−7 1.0 × 10−7
Slope from Figure 5(b) 0.65 ± 0.11 0.62 ± 0.07 1.0 ± 0.13
IC
50
(𝜇mol L−1) 3.6 ± 1.4 4.7 ± 1.6 2.8 ± 1.3
Affinity constant (𝐾
𝑎
, 𝜇mol−1) 0.30 ± 0.05 0.27 ± 0.04 0.33 ± 0.05
Linear detection range∗ (𝜇mol L−1) 0.47–24.6 0.74–40.7 0.52–43.7
∗20–80% of the%𝐼 curve.



































Figure 5: Dose-response curves of the ci-ELISAs under the samemolar concentration of epitope in an assay. Absorbance curve (a); inhibition
curve (b). e = the molar concentration of cysBPAv-AuNP-190 is 5.3 × 10−10mol L−1 (the molar concentration of epitope in an assay: 1.0 ×
10−7mol L−1); ◻ = 2.6 × 10−10mol cysBPAv-AuNP-396 L−1 (the molar concentration of epitope in an assay: 1.0 × 10−7mol L−1); 󳵳 = 1.3 ×
10−10mol cysBPAv-AuNP-801 L−1 (the molar concentration of epitope in an assay: 1.0 × 10−7mol L−1).
via multivalent interaction between antibody and surface
epitopes. The surface coverage of epitopes per nanoparticles
is, in effect, a way of increasing the local concentration
of the epitope in the vicinity of the antibody such that
the equilibrium is biased to form a complex as well as
influencing an IC
50
.The assaymolar concentration of epitope
was the most influential factor that determined the linear
detection range and an IC
50
of the competitive inhibition
assay. Of the three factors, the assay molar nanoparticle
concentration is the dominant factor of the affinity constant
of antibody binding to the surface epitopes, while it also had
the least effect on the assay sensitivity as long as the molar
nanoparticle concentration in an assay was within the ranges
of nanoparticle stability and below the saturation point of
antibody binding sites.
This study showed that small epitope functionalized
nanoparticles behave much like hapten-protein conjugates
in a competitive inhibition assay, which also allowed precise
control of surface chemistry. As indicated by the results
of this study, nanoparticles with optimum surface epitope
coverage are critical for the fabrication of immunosensors
based on a competitive inhibition format. Additionally, the
two-antibody competitive inhibition assay devised in this
study was determined to be a simple and useful tool for
characterizing targeted nanoparticles for the competitive
inhibition assay.
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